Quotient Ltd
NASDAQ:QTNT
Intrinsic Value
Quotient Ltd. is a commercial-stage diagnostics company, which provides immunohematology products to hospitals and blood banks. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of QTNT.
Quotient Ltd's market capitalization is 141.3k USD.
QTNT stock price is 0.04 USD.
QTNT.
QTNT. Open DCF Valuation
QTNT. Open Relative Valuation
QTNT.
QTNT's short-term assets (40m USD) exceed its short-term liabilties (30m USD).
QTNT has positive Gross Profit for the last twelve months.
QTNT has negative Operating Income for the last twelve months.
QTNT has negative Net Income for the last twelve months.
QTNT's ROE (Return on Equity) for the past 12 months is very high and is equal to 74%.
QTNT's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -114%.
QTNT's long-term liabilties (328m USD) exceed its long-term assets (119m USD).
QTNT has negative Free Cash Flow for the last twelve months.
QTNT has positive Net Debt. This means that the company has more debt (264m USD) than cash and short-term investments (12m USD).
QTNT has very high three-year average ROE (Return on Equity): 139%. The company is very efficient at transforming stockholders' equity into net income.
QTNT has negative three-year average ROIC (Return on Invested Capital): -93%. The company is not efficient at using invested capital to generate operating income.
QTNT's D/E (Debt to Equity) is very low and is equal to -1.26.
QTNT's Altman Z-Score is very low and is equal to -12.59.
Fundamental Analysis
Quotient Ltd
Balance Sheet Decomposition
Quotient Ltd
| Current Assets | 40.5m |
| Cash & Short-Term Investments | 11.9m |
| Receivables | 6.6m |
| Other Current Assets | 21.9m |
| Non-Current Assets | 78.8m |
| Long-Term Investments | 15.6m |
| PP&E | 57.5m |
| Intangibles | 435k |
| Other Non-Current Assets | 5.4m |
| Current Liabilities | 29.6m |
| Accounts Payable | 2.8m |
| Accrued Liabilities | 26.5m |
| Other Current Liabilities | 341k |
| Non-Current Liabilities | 298.6m |
| Long-Term Debt | 263.7m |
| Other Non-Current Liabilities | 34.8m |
Earnings Waterfall
Quotient Ltd
|
Revenue
|
37.4m
USD
|
|
Cost of Revenue
|
-37.1m
USD
|
|
Gross Profit
|
279k
USD
|
|
Operating Expenses
|
-117.2m
USD
|
|
Operating Income
|
-116.9m
USD
|
|
Other Expenses
|
-7.1m
USD
|
|
Net Income
|
-124m
USD
|
Free Cash Flow Analysis
Quotient Ltd
What is Free Cash Flow?
QTNT Profitability Score
Profitability Due Diligence
Quotient Ltd's profitability score is 42/100. The higher the profitability score, the more profitable the company is.
Score
Quotient Ltd's profitability score is 42/100. The higher the profitability score, the more profitable the company is.
QTNT Solvency Score
Solvency Due Diligence
Quotient Ltd's solvency score is 37/100. The higher the solvency score, the more solvent the company is.
Score
Quotient Ltd's solvency score is 37/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
QTNT Price Targets Summary
Quotient Ltd
Ownership
QTNT Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
QTNT Price
Quotient Ltd
| Average Annual Return | -28% |
| Standard Deviation of Annual Returns | 37.31% |
| Max Drawdown | -100% |
| Market Capitalization | 141.3k USD |
| Shares Outstanding | 3 531 710 |
| Percentage of Shares Shorted | 5.5% |
Company Profile
Quotient Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Quotient Ltd. is a commercial-stage diagnostics company, which provides immunohematology products to hospitals and blood banks. The firm focuses on blood grouping and donor disease screening, which is referred to as transfusion diagnostics. The company is engaged in developing, manufacturing and commercializing conventional reagent products used for blood grouping within the global transfusion diagnostics market. The company is engaged in developing MosaiQ, which is its technology platform. The firm develops, manufactures and commercializes the products, including antisera products, reagent red blood cells, whole blood controls and ancillary products. Additionally The Company develops, manufactures and sells conventional reagent products to original equipment manufacturers (OEMs).
You don't have any saved screeners yet
